Aline Yen Ling Wang

Biography: Dr. Aline Yen Ling Wang received her Ph.D. in immunology from the Taiwan National Defense Medical Center in Taipei which saw her gain a further research fellowship at the John Hopkins Hospital in the USA. Her research interests include the field of translational medicine, especially in the field of immunology had led her to pursue a career in transplantation research. Her focus currently is on vascularized composite allotransplantation. She has published in many good journals in both immunology and clinical plastic surgery journals and written several book chapters in this field with multiple presentations in international meetings. In order to contribute to the clinical work of autoimmunity and transplantation immunity, she is committed to studying the treatment and prevention strategies of autoimmune diseases and transplant rejection. The most representative strategies are as follows: 1. Establishment and production of fusion proteins such as PLAD and DcR3 fusion proteins and applied to autoimmune diseases such as type 1 diabetes, multiple sclerosis, and colitis animal models and displayed significant prevention. 2. Stem cell therapies such as induced pluripotent stem cells (iPSCs) and Wharton's jelly mesenchymal stem cells (WJ-MSCs) can significantly promote the recovery and regeneration of sciatic nerve and the effects of stem cell therapies on the survival of composite allografts and the underlying mechanisms are also studying. 3. Clarify the molecular mechanism between Blimp-1 and T cell-induced allograft tolerance and further design the tolerance induction strategies. 4. Applications of modified mRNA (modRNA) in transplant immunology and peripheral nerve regeneration. Research interest: Transplant immunology, autoimmunity, peripheral nerve regeneration, mesenchymal stem cells, induced pluripotent stem cells, modified mRNA, peripheral nerve regeneration, heart transplantation, and vascularized composite allotransplantation (VCA).

Papers in database

1

Primary author

1 paper

Years active

2026